Considerations in darbepoetin alfa cost and reimbursement: A model for pharmacy managers

被引:10
作者
Anderson, ER
Gibson, G
机构
[1] Lahey Clin Med Ctr, Dept Pharm Serv, Burlington, MA 01805 USA
[2] Univ Penn, Ctr Managed Pharmaceut & Econ Outcomes, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Pharm, Philadelphia, PA 19104 USA
来源
PHARMACOTHERAPY | 2003年 / 23卷 / 12期
关键词
darbepoetin alfa; pharmacoeconomics; reimbursement analysis;
D O I
10.1592/phco.23.16.119S.31972
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
With health care administrators focusing on the financial aspects of patient care, pharmacy budget managers must be able to evaluate all financial implications of drugs under formulary review. Clinical considerations, dosing equivalency, direct and indirect costs, payer mix, and reimbursement level are issues that should be considered by a multidisciplinary team. A pharmacoeconomic evaluation of darbepoetin alfa compared with epoetin alfa is presented as a model to help pharmacy budget managers address these issues and develop an evaluation of two high-cost drugs to determine which would be the better agent to have on their formulary.
引用
收藏
页码:119S / 124S
页数:6
相关论文
共 14 条
  • [1] *AMG INC, 2002, AR DARB ALF PACK INS
  • [2] [Anonymous], 2002, Understanding Health Policy
  • [3] Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
    Crawford, J
    Cella, D
    Cleeland, CS
    Cremieux, PY
    Demetri, GD
    Sarokhan, BJ
    Slavin, MB
    Glaspy, JA
    [J]. CANCER, 2002, 95 (04) : 888 - 895
  • [4] Glaspy JA, 2002, ONCOLOGY-NY, V16, P71
  • [5] Glaspy JA, 2002, ONCOLOGY-NY, V16, P23
  • [6] Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
    Glaspy, JA
    Jadeja, JS
    Justice, G
    Kessler, J
    Richards, D
    Schwartzberg, L
    Tchekmedyian, NS
    Armstrong, S
    O'Byrne, J
    Rossi, G
    Colowick, AB
    [J]. BRITISH JOURNAL OF CANCER, 2002, 87 (03) : 268 - 276
  • [7] Korcok M, 2003, CAN MED ASSOC J, V168, P472
  • [8] Mirtsching B, 2002, ONCOLOGY-NY, V16, P31
  • [9] RIZZO JD, 2002, J CLIN ONCOL, V20, P1
  • [10] Applied pharmacoeconomics: Evaluation and use of pharmacoeconomic data from the literature
    Sanchez, LA
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1999, 56 (16) : 1630 - 1640